#	Pagina
attuale pagina	/open-h2020/projects/212680/index.html

Opendata, web and dolomites

COLOSSUS SIGNED

Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

COLOSSUS project word cloud

Explore the words cloud of the COLOSSUS project. It provides you a very rough idea of what is the project "COLOSSUS" about.

wild metastatic tools network treatment associations fluoruracil once actionable context validated patient outcome assays stable sme limited microsatellite power primarily approximately clinical computational global integrate chemotherapy difficult colorectal mutant multidimensional options optimization stratification stratified 2012 mutations longitudinal 420 therapeutic mt interventions feasible therapy colossus cancer biomedicine resistant clinically personalised dependences harness patients commercialisation setting smes subtypes interrogated crc mcrc will prevalence data significantly mss trial disease 55 xenograft total mechanism signalling regulatory classifiers prediction economic bevacizumab cancers deaths omics harbour biomarkers ras participating strategies 150 newly commercially healthcare

Project "COLOSSUS" data sheet

The following table provides information about the project.

Coordinator	ROYAL COLLEGE OF SURGEONS IN IRELAND Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 website: www.rcsi.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	https://www.colossusproject.eu/
Total cost	5˙996˙359 €
EC max contribution	5˙996˙359 € (100%)
Programme	1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
Code Call	H2020-SC1-2017-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ROYAL COLLEGE OF SURGEONS IN IRELAND ROYAL COLLEGE OF SURGEONS IN IRELAND Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 website: www.rcsi.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	1˙255˙454.00
2	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON Organization address address: CALLE NAZARET 115-117 city: BARCELONA postcode: 8035 website: http://www.vhio.net contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	836˙305.00
3	VIB VZW VIB VZW Organization address address: RIJVISSCHESTRAAT 120 city: ZWIJNAARDE - GENT postcode: 9052 website: www.vib.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ZWIJNAARDE - GENT)	participant	668˙549.00
4	UNIVERSITA DEGLI STUDI DI TORINO UNIVERSITA DEGLI STUDI DI TORINO Organization address address: VIA GIUSEPPE VERDI 8 city: TORINO postcode: 10124 website: www.unito.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (TORINO)	participant	468˙676.00
5	HALIODX HALIODX Organization address address: 163 AVENUE DE LUMINY PARC SCIENTIFIQUE DE LUMINY LUMINY BIOTEC ENTREPRISES city: MARSEILLE postcode: 13288 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (MARSEILLE)	participant	417˙668.00
6	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN Organization address address: BELFIELD city: DUBLIN postcode: 4 website: www.ucd.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	participant	388˙591.00
7	OPTIMATA LTD OPTIMATA LTD Organization address address: 20 ZICHRON YAA'KOV ST. city: TEL AVIV postcode: 6299920 website: www.optimata.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (TEL AVIV)	participant	329˙268.00
8	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL Organization address address: OLD BROMPTON ROAD 123 city: LONDON postcode: SW7 3RP website: www.icr.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	300˙146.00
9	GENEXPLAIN GMBH GENEXPLAIN GMBH Organization address address: AM EXER 19 B city: WOLFENBUTTEL postcode: 38302 website: www.genexplain.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WOLFENBUTTEL)	participant	284˙468.00
10	IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG Organization address address: INNOVATION HOUSE DCU ALPHA FINGLAS ROAD OLD city: DUBLIN 11 postcode: D11 KXN4 website: www.icorg.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN 11)	participant	248˙413.00
11	PINTAIL LTD PINTAIL LTD Organization address address: SPRINGHILL AVENUE 77 city: Blackrock postcode: A94 K542 website: www.pintail.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (Blackrock)	participant	233˙468.00
12	EPIGENOMICS AG EPIGENOMICS AG Organization address address: KLEINE PRAESIDENTENSTR 1 city: BERLIN postcode: 10178 website: www.epigenomics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	230˙518.00
13	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	178˙268.00
14	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 website: www.uni-heidelberg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HEIDELBERG)	participant	156˙560.00

Map

Project objective

Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cases, it is estimated that approximately 50-55 % harbour RAS mutations. Current treatment for RAS mutant (mt) metastatic(m) CRC is primarily based on 5-fluoruracil based chemotherapy /- bevacizumab. However, there are currently limited treatment options once cancers have become resistant. Moreover, while therapy optimization strategies in RAS wild-type CRC patients are feasible, targeted treatment of microsatellite stable (MSS) RAS mt disease is difficult and has not evolved significantly in recent years. COLOSSUS will deliver novel concepts for disease-mechanism based patient stratification in MSS RAS mt mCRC to address the need for stratified or personalised therapeutic interventions in this setting. The consortium will integrate multidimensional and longitudinal omics data to identify new MSS RAS mt specific subtypes with unique signalling dependences. We will harness the power of systems biomedicine, network analysis and computational modelling to identify new actionable pathways, biomarkers and targets across subtypes. These targets will be interrogated in state of the art pre-clinical patient derived xenograft studies. Newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial. SME partners will develop clinically relevant and commercially viable assays for outcome prediction and stratification of MSS RAS mt patients based on novel classifiers. The impact of assays on CRC associated healthcare costs will further be assessed. Patient associations will be included and the proposal will consider regulatory aspects and commercialisation opportunities, in particular for participating SMEs. mCRC is a complex disease having high prevalence and high economic impact both within a European and global context.

Deliverables

List of deliverables.
Website/online assets (maintained and updated during project)	Websites, patent fillings, videos etc.	2020-01-14 15:07:32

Take a look to the deliverables list in detail: detailed list of COLOSSUS deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Elke Burgermeister, Francesca Battaglin, Fagr Eladly, Wen Wu, Frank Herweck, Nadine Schulte, Johannes Betge, Nicolai HÃ¤rtel, Jakob N. Kather, Cleo-Aron Weis, Timo Gaiser, Alexander Marx, Christel Weiss, Ralf Hofheinz, Ian S. Miller, Fotios Loupakis, Heinz-Josef Lenz, Annette T. Byrne, Matthias P. Ebert Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A published pages: 139-154, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2019.07.004	EBioMedicine 45	2019-10-01
2019	Irene Catalano, Livio Trusolino The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy published pages: 1-3, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2019.06.001	Cancer Cell 36/1	2019-10-01
2018	Florent Petitprez, Cheng-Ming Sun, Laetitia Lacroix, Catherine SautÃ¨s-Fridman, AurÃ©lien de ReyniÃ¨s, Wolf H. Fridman Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00390	Frontiers in Oncology 8	2019-10-01
2019	Alice C. O\'Farrell, Ian S. Miller, Rhys Evans, Marina Alamanou, Maurice Cary, Girish Mallya Udupi, Adam Lafferty, Naser Monsefi, Mattia Cremona, Jochen H. M. Prehn, Henk M. Verheul, William M. Gallagher, Mathias Gehrmann, Annette T. Byrne Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Preâ€Clinical Detection of Offâ€Target Toxicities Associated with Sunitinib Malate published pages: 1800159, ISSN: 1862-8346, DOI: 10.1002/prca.201800159	PROTEOMICS â€“ Clinical Applications	2019-10-01
2018	M. Sturrock, I. S. Miller, G. Kang, N. Hannis Arbaâ€™ie, A. C. Oâ€™Farrell, A. Barat, G. Marston, P. L. Coletta, A. T. Byrne, J. H. Prehn Anti-angiogenic drug scheduling optimisation with application to colorectal cancer published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-29318-5	Scientific Reports 8/1	2019-10-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOSSUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOSSUS" are provided by the European Opendata Portal: CORDIS opendata.